Copyright
©The Author(s) 2015.
World J Stem Cells. Jan 26, 2015; 7(1): 106-115
Published online Jan 26, 2015. doi: 10.4252/wjsc.v7.i1.106
Published online Jan 26, 2015. doi: 10.4252/wjsc.v7.i1.106
Step-Days | Procedure |
1-3.5 prior to step 2 | EB formation is stimulated by plating hESCs on ultra-low attachment plates with serum-free medium supplemented with BMP-4, VEGF165 and basic FGF; 48 h later, half of the medium renewed and accreted with SCF, thrombopoietin and FLT3 ligand; EBs are formed and induced to differentiate to hemangioblasts |
2-d 0 to 10 | EBs formed are dissociated with trypsin and a single cell suspension is obtained; The cells are re-suspended in appropriate medium and further put in contact with BGM with added FGF and t-PTD-HoxB4 fusion protein, where they are expanded for 10 d; The hemangioblasts are expanded enough after this period of 10 d |
3- d 11 to 20 | Differentiation to erythroid cells may be achieved by culturing the hemangioblasts obtained in step 2 for 5 d with the addition of BGM supplemented with Epo to the medium used in step 2; The cells are then expanded for up to seven more days on Stemline II-based medium supplemented with SCF, Epo and methylcellulose |
4-d 21 | Erythroid cells obtained after step 3 were suspended in IMDM with 0.5% BSA in order to be collected by centrifugation The cells are washed with IMDM and BSA and normally plated so that non-erythroid cells adhere, allowing the non-adherent to be separated by collecting the medium and centrifugation |
Step | Procedure |
1 | Hemangioblasts obtained on day 7 of the procedures described in Table 1 are filtered and plated with Stemline II medium supplemented with inositol, folic acid, monothioglycerol, transferrin, insulin, ferrous nitrate, ferrous sulphate and BSA, along with penicillin-streptomycin solution |
2 | For 7 d, the medium described in step 1 had hydrocortisone, SCF, interleukin-3 and Epo added; Cell density was kept at 106 cells/mL |
3 | After the 7th day, SCF and interleukin-3 were no longer added to the medium |
4 | The cells were co-cultured with human mesenchymal stem cells or OP9 mouse stromal cells at different days between days 19 and 36; |
Medium was composed as described in Step 1 with the addition of Epo |
Hematopoietic lineage | Culture conditions for ESCs | Culture conditions for iPSCs | Cytokines used in ESC differentiation | Cytokines used in iPSC differentiation | Ref. |
Erythrocytes | Cells grown initially on mitomycin-treated Mouse Embryonic Fibroblasts; BGM and Stemline II media are used; Final step was in co-culture with OP9 cells or human mesenchymal stem cells | Cells are grown in co-culture with human fetal liver-derived feeder layer | BMP-4, VEGF165, FGF, thrombopoietin, FLT-3L, t-PTD-HoxB4 fusion protein, Epo, IL-3 | IL-3, SCF, Epo, BMP-4, Insulin-like growth factor-1 | [28,31,32,74] |
Megakaryocytes | Cells are grown in co-culture with OP9 stromal cells | Feeder-free culture in serum-free Stemline medium or in OP9 or C3H10T1/2 | IL-6, IL11 and thrombopoietin | BMP-4, VEGF, FGF, SCF, thrombopoietin, FLT-3L, IL-11 | [35,75,76] |
Mast cells | Cells are grown in co-culture with OP9 stromal cells | Mice iPSCs were initially co-cultured in on mitomycin-treated Mouse Embryonic Fibroblasts with LIF added. In the final step, OP9 cells were used as feeder layer | SCF, IL-6, IL-3 and FLT-3L | IL-3, IL-6 and SCF | [43,44,77] |
Macrophages | Cells are grown in co-culture with OP9 stromal cells, but in an alternative method, no feeder layer was used, EBs were produced by the spinning method | Cells are grown in co-culture with OP9 stromal cells | IL-3 and M-CSF | FGF, BMP-4, VEGF, IL-3, IL-6, IL-11, SCF | [45,78] |
T lymphocytes | Cells are grown in co-culture with OP9 stromal cells | Initial culture was done on irradiated SNL76/7 cells and further steps on OP9-DL1 cells | FLT-3L, IL-7 and SCF | FLT-3L, IL-5 | [49-52,79] |
B lymphocytes | Cells are grown in co-culture with OP9 stromal cells | Cells are grown in co-culture with OP9 stromal cells | FLT-3L, IL-7 | FLT-3L, IL-3, IL-7 and SCF | [53-55,80] |
Eosinophils | Cells are grown in co-culture with OP9 stromal cells | No established protocol | IL-5, IL-3, GM-CSF and Eotaxin | No established protocol | [56] |
Neutrophils | Cells are grown in co-culture with OP9 stromal cells | Cells are grown in co-culture with OP9 stromal cells | BMP-4, SCF, FLT-3L, IL-6, IL-6 receptor fusion protein, thrombopoietin and G-CSF | VEGF, IL-3, SCF, thrombopoietin and G- CSF | [59,81] |
Dendritic cells | Cells are grown in co-culture with OP9 stromal cells | Cell culture was feeder free, initially on mTeSR1 medium and posteriorly using X-VIVO 15 medium | GM-CSF, IL-4, TNF-α | BMP-4, VEGF, SCF, GM-CSF, IL-4 | [60,61,82] |
Natural killer Cells | Cells are grown in co-culture with M210-B4 cells initially and AFT024 cells in the final step | Cells are grown in co-culture with M210-B4 cells initially and AFT024 cells in the final step | IL-3, IL-7, IL-15, SCF and FTL-3L | IL-3, IL-7, IL-15, SCF and FTL-3L | [63,83] |
- Citation: Souza GT, Maranduba CP, Souza CM, Amaral DLASD, Guia FCD, Zanette RSS, Rettore JVP, Rabelo NC, Nascimento LM, Pinto &FN, Farani JB, Neto AEH, Silva FS, Maranduba CMDC, Atalla A. Advances in cellular technology in the hematology field: What have we learned so far? World J Stem Cells 2015; 7(1): 106-115
- URL: https://www.wjgnet.com/1948-0210/full/v7/i1/106.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v7.i1.106